Minerva Neurosciences Stock News

The FDA approves Marinus' (MRNS) Ztalmy (ganaxolone) to treat seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. The company's shares gain following the announcement.

Minerva Neurosciences (NERV) delivered earnings and revenue surprises of 40% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Minerva Neurosciences press release (NERV): Q4 GAAP EPS of -$0.50 misses by $0.31.Cash, equivalents and restricted cash as of December 31, 2021 were approximately $60.9 million,…

WALTHAM, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV) a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat c

WALTHAM, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV) a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system disorders, today reported key business updates and financial results for the fourth quarter ended December 31, 2021. The Company is not hosting a call this quarter as it prepares for a meeting with the FDA and anticipates providing an update after the meeting, as appropriate.

Minerva Neurosciences (NERV) delivered earnings and revenue surprises of 40% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Trial Results Confirm the Potential of Roluperidone To Treat Negative Symptoms and Improve Everyday Functioning in Patients with Schizophrenia Trial Results Confirm the Potential of Roluperidone To Tr

WALTHAM, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV ), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that results from the Phase 3 clinical trial of roluperidone to treat negative symptoms in patients with schizophrenia have been published in Schizophrenia Bulletin . The study authors conclude that this study confirms the potential of roluperidone to treat the negative symptoms in individuals with schizophrenia as well as improve everyday functioning. The publication, entitled, " Efficacy and Safety of Roluperidone for the treatment of negative symptoms of schizophrenia ," reports on the Phase 3 placebo-controlled multi-national trial of roluperidone, a compound with antagonist properties for 5-HT 2A , sigma 2 and α 1A -adrenergic receptors, targeting negative symptoms in patients with schizophrenia. The goal of the trial was to confirm the findings of a previous Phase 2 trial with a similar patient population and methodology that had demonstrated roluperidone superiority over placebo.

Zacks Investment Research upgraded shares of Minerva Neurosciences (NASDAQ:NERV) from a hold rating to a buy rating in a research note published on Thursday morning, Zacks.com reports. They currently have $1.00 target price on the biopharmaceutical companys stock. According to Zacks, Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development [] The post Minerva Neurosciences (NASDAQ:NERV) Upgraded at Zacks Investment Research appeared first on ETF Daily News .

SeaChange International, Inc. (NASDAQ:SEAC) with the stream of -12.21% also noticed, India Minerva Neurosciences, Inc. (NASDAQ:NERV) encountered a rapid change of -3.23% in the last hour of Tuesdays trading session. The post Investors Alert (ATR Analysis): SeaChange International, Inc. (NASDAQ:SEAC), Minerva Neurosciences, Inc. (NASDAQ:NERV) appeared first on Stocks Equity .

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Alluring stocks: Ambev S.A. (NYSE:ABEV -3.14%), Minerva Neurosciences, Inc. (NASDAQ:NERV -1.64%) appeared first on Stocks Equity .

Minerva Neurosciences, Inc. (NASDAQ:NERV) Director David Kupfer sold 55,635 shares of the stock in a transaction dated Wednesday, December 1st. The shares were sold at an average price of $0.88, for a total transaction of $48,958.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through []

Zacks Investment Research upgraded shares of Minerva Neurosciences (NASDAQ:NERV) from a hold rating to a buy rating in a report released on Friday morning, Zacks.com reports. They currently have $1.00 target price on the biopharmaceutical companys stock. According to Zacks, Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and []

Zacks Investment Research cut shares of Minerva Neurosciences (NASDAQ:NERV) from a buy rating to a hold rating in a research report report published on Wednesday, Zacks.com reports. According to Zacks, Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central []

Minerva Neurosciences (NASDAQ:NERV) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a note issued to investors on Friday, Zacks.com reports. The brokerage currently has a $1.00 target price on the biopharmaceutical companys stock. Zacks Investment Researchs price objective indicates a potential upside of 7.99% from the companys current []